This sponsored supplement was produced by Focus Reports.
Project Director: Léa Boubon
Project Editor: Nicolas Carayon; James Waddell; Manuel Mendoza
For exclusive interviews and more info, please log onto http://Pharma.FocusReports.net/ or write to firstname.lastname@example.org
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which
epitomizes a changing continent. At one time an enigmatic behemoth cast behind an iron curtain, Poland's accession to the
European Union in 2004 has injected its economy with new levels of competition and investment. A population of 38 million
citizens, in turn, offers an enticing market for companies looking to expand east. The country's leaders proudly boast that
Poland was the only EU economy to grow in 2009—the nadir of the financial crisis—and last year Poland surpassed the Netherlands
as Europe's sixth-largest economy. Today the pharmaceutical industry looks to Poland for a skilled pool of human resources,
an eastern platform for competitive manufacturing, and high-quality clinical trials. Yet there is still much work ahead, and
in order to fully embrace the future the industry must overcome certain communication barriers stemming from the country's
long, closed-market past. Greater room for innovation and increased dialogue between business and government are necessary
steps to truly awake Europe's sleeping giant.
Niebianska Parmiec (Celesitial Memory) by Elzbieta Murawska
ECONOMIC REVOLUTION ...
The past two decades have brought about sweeping changes and lasting benefits for Poland through its transition to a market-based
economy and, more recently, incorporation into the European Union. The Balcerowicz Plan of "shock therapy" undertaken in the
early 1990s liberalized trade and privatized former public assets, thereby increasing industrial competition and promoting
foreign direct investment. Poland was widely lauded as a success story among transitional economies. Since 2004, EU membership
has compounded the positive effect of capitalist reforms by granting the Polish economy access to structural funds. Today
the country is the largest beneficiary of EU funds among the 27 member states, receiving approximately 20% of total EU financial
support. While GDP per capita in Poland is still below the EU average, it is on par with that of its neighboring Baltic states.
With 1.5% GDP growth in 2009, Poland was the best-performing European economy during the global financial crisis. Peter Koetsier,
general manager of Bristol-Myers Squibb Poland beams that "the country has gone through a remarkable transition in the past
twenty years, if you consider the huge steps forward in terms of infrastructure and the financial and legal systems. I look
forward to continued progress in healthcare that will see the people of Poland reach health outcome levels more akin to other
Ewa Kopacz, Minister of Health
... AND PHARMACEUTICAL EVOLUTION
Valued at slightly over €5 billion, Poland is the sixth-largest drug market in Europe, according to classifications by the
European Pharmaceutical Market Research Association. The country's pharmaceutical industry is shaped by high generic penetration
and government-dictated cost-containment which limits market access to innovation.
However, compared to similar-size markets such as Spain, Poland has an uncharacteristically high penetration of generics,
which account for 85% of volume and 66% of value, according to PZPPF, the leading association for generics companies in Poland.
As PZPPF president Cezary Slediewski explains, the dyamics behind high generic rates stem from "a patent system and data exclusivity
which allowed Polish companies and importers to introduce generics earlier on in Poland than in Western European countries.
There are some molecules in Poland that are already generics, whereas in Western Europe, generics for the very same molecule
are not yet in the market."
Waldemar Pawlak, Minister of Economy
Additionally unique to Poland are minimal price spreads between generic and innovative drugs. Pawel Sztwiertnia, general director
of INFARMA, the leading association for R&D companies in Poland, notes that "the average price of innovative originator products
is one of the lowest in Europe. Subsequently, there are expensive generic products in Poland when compared to the average
originator product prices in Europe. This is due to a market structure overpowered by generics. IMS Health data demonstrates
that the average generic price is roughly 70% of that of an originator."
Per capita expenditure on healthcare and pharmaceuticals—less than $100—is one of the lowest in the OECD, three times less
than Slovakia and the Czech Republic, and six times less than France and Germany.
POLAND - market value mln EURO, ex-manufacturer net prices
As Sztwiertnia explains, "The system in Poland reduces the already very limited window for innovative products. When a company
manages to establish its product on the reimbursement list, it can then be prescribed by any doctor and be made available
in every pharmacy. Thus, from the government's perspective, there is always the fear that reimbursement costs will skyrocket
if a new product is added to the list. Reimbursement costs are very difficult to control; monitoring of prescriptions is practically
nonexistent in Poland. There are no specialized categories of drugs that specialists could prescribe under certain conditions.
For instance, because many patients need treatment for diabetes or cardiovascular diseases, the government is afraid that
costs could grow out of control."
The federal government notes the necessary limitations on health expenditures in even the most developed countries. "The reasons
for this are, among others, constantly growing health needs resulting from the aging of the population, quickly growing costs
of medical technologies, and financial expectations of medical staff," cites Ewa Kopacz, Poland's minister of health.
POLAND - share of generic products
Despite the prevalence of generics, INFARMA assesses that market growth for innovative drugs is quite sustainable in Poland.
Compound annual growth of 8.5% for innovative medicines from 2007 to 2010 exceeds EU-15 markets over the same period, a trend
that reflects growth in value more so than volume.